EPO and myelodysplastic syndrome: Because Tfrc expression in bone marrow is mainly EPO-mediated (Chan et al., 1994), we anticipate that erythroblast Tfrc expression is elevated in MDS as a consequence of high EPO, consequently decreased in DFP-treated relative to untreated MDS mice.